Results 241 to 250 of about 6,017,024 (357)

A Call for a Better PoPH Risk Assessment Model, and Treatment Direction. [PDF]

Pulm Circ
Lai YK.
europepmc   +1 more source

Evaluation of military field-water quality: Volume 5, Infectious organisms of military concern associated with consumption: Assessment of health risks, and recommendations for establishing related standards

, 1986
R Cooper, Adam W. Olivieri, R. E. Danielson, P G Badger, Robert C. Spear, Steve Selvin   +5 more
openalex   +2 more sources

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

PREOPERATIVE ASSESSMENT OF RISK FACTORS

, 1988
R. J. Smith
openalex   +1 more source

A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester, Kevin Talbot, Martin R. Turner, Alexander G. Thompson, the Pooled Resource Open‐Access ALS Clinical Trials Consortium   +4 more
wiley   +1 more source

Mutational repair in mammals and its bearing on risk assessment

, 1977
W. L. Russell
openalex   +1 more source

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

Characterization and health risk assessment of airborne microplastics in Delhi NCR. [PDF]

Sci Rep
Rao MN, Ghude SS, Nivdange SS, Panchang R, Pipal AS, Mukherjee A, Sharma H, Kumar V.   +7 more
europepmc   +1 more source

Evolution of environmental epidemiologic risk assessment.

, 1985
Henry A. Anderson
openalex   +1 more source